By Cecilia Butini


Sanofi SA on Thursday backed its yearly guidance and reported higher sales for the first quarter, driven by its specialty care and vaccine businesses.

The French pharma company confirmed that it expects 2023 business earnings per share--a key metric--to grow low-single digit at constant exchange rates, barring unforeseen major adverse events.

For the first quarter, it posted sales of 10.22 billion euros ($11.28 billion), up from EUR9.67 billion in the same quarter a year prior. Analysts polled by FactSet had expected sales of EUR10.50 billion. Net income came in flat on year at EUR2 billion, but business net income grew to EUR2.70 billion from EUR2.42 billion the year prior, the company said.

The key metric of business earnings per share grew 11% to EUR2.16 in the quarter, said Sanofi.

Chief Executive Paul Hudson said that Sanofi's best-selling allergy drug Dupixent is on track to achieve a EUR10 billion sales objective for this year. Sales in the vaccine business were up 15% in the quarter, reflecting the recovery of booster and travel vaccines, and Covid-19 vaccine shipments in Europe, said the company.


Write to Cecilia Butini at


(END) Dow Jones Newswires

April 27, 2023 02:08 ET (06:08 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Set 2023 até Out 2023 Click aqui para mais gráficos Sanofi.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Out 2022 até Out 2023 Click aqui para mais gráficos Sanofi.